Latest Cost Reduction News

South Harz Potash Limited has raised A$1.25 million to fund exploration at its newly licensed copper-gold projects in Sweden, signalling a strategic pivot towards critical minerals and a planned rebrand to Turnstone Resources.

Spenda Limited has successfully raised $1.4 million through a private placement, supported by both new and existing sophisticated investors, including key directors. The funds will fuel the company’s commercialisation efforts and strengthen its working capital position.

Pure Foods Tasmania reports a significant operational turnaround in 1H FY26, driven by strategic cost reductions, expanded distribution deals with major retailers, and the acquisition of premium ice cream brand Elato.

Verbrec Limited reports a strong first half of FY2026, with revenue climbing to $46.1 million and EBITDA more than doubling, driven by the strategic acquisition of Alliance Automation.

The Star Entertainment Group reports a $110 million statutory loss for H1 FY26 as it undertakes major operational restructuring and seeks refinancing amid challenging market conditions.

The Star Entertainment Group reported a 10% drop in H1 FY26 revenue, offset by a 71% improvement in EBITDA, while navigating ongoing licence suspensions and a critical refinancing process.

Resolute Mining Limited reported a robust financial turnaround in 2025, posting a $126.7 million net profit driven by higher gold prices and cost efficiencies despite lower production volumes. The granting of the Doropo mining permit and strategic asset sales mark key milestones in its West African expansion.

ClearVue Technologies reported a 9% reduced half-year loss of $5.25 million, while pushing forward with significant advancements in its solar glass technology and expanding global licensing partnerships.

Epsilon Healthcare Limited has reported a robust recovery in 2025, with revenue climbing 68% to $9.39 million and net losses shrinking by 63%, driven by growth in contract manufacturing and a new pharmacy division.

SOCO Corporation reports a 12% revenue drop to $9.7 million for H1 FY26, weighed down by a $4.6 million goodwill impairment linked to AxSym. Despite growth in core consulting, the company posted a significant net loss and undertook restructuring to align costs.

Botanix Pharmaceuticals reports a surge in Sofdra sales driving revenue to $16.5 million, yet the company records a $33.2 million loss amid expanded marketing and operational costs. A $45 million capital raise aims to support growth and supply chain improvements.

IMEXHS Limited delivered FY25 results at the top end of guidance, reporting a 10% revenue increase and a tripling of underlying EBITDA. The company’s software and radiology services both showed solid growth, setting the stage for an optimistic FY26 outlook.